iBio, Inc. (IBIO) Stock: A Biotech Stock That’s Falling


iBio, Inc. (IBIO) is falling in the market today. The stock, focused on the biotechnology space, is presently trading at $0.16 after tumbling -5.94% so far in today’s session. In terms of biotech companies, there are a number of factors that have the potential to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines relating to IBIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-25-19 08:30AM iBio, Inc. Prices $5,000,000 Public Offering
Oct-22-19 04:30PM iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
Sep-19-19 01:58PM One Thing To Remember About The iBio, Inc. (NYSEMKT:IBIO) Share Price
Sep-17-19 04:15PM iBios Collaboration with South Africas AzarGen Biotechnologies Advances to Next Stage
Aug-26-19 05:30PM iBio and CC-Pharming Expand Business Collaboration in China

Nonetheless, any time investors are making a decision to invest, prospective investors should take a look at much more than just news, this is especially the case in the highly speculative biotechnology space. Here’s what’s going on with iBio, Inc..

Recent Movement From IBIO

Although a move down on a single session, like the fall that we’re seeing from iBio, Inc. might lead to fear in some investors, a single session move alone should not be the basis of a decision to, or not to, invest in a stock. It’s always important to take a look at trends experienced by the stock further out than a single trading session. When it comes to IBIO, below are the movements that we’ve seen:

  • Weekly – Over the past 7 days, IBIO has generated a change in price amounting to -66.31%.
  • Monthly – The return on investment from iBio, Inc. throughout the past 30 days works out to -70.24%.
  • Past Quarter – Throughout the past quarter, the stock has generated a return on investment that comes to -76.44%
  • Past Six Months – Throughout the previous 6 months, we have seen a change that amounts to -81.18% from the company.
  • YTD – Since the close of last year IBIO has generated a ROI of -78.76%.
  • Full Year – Finally, in the past year, we’ve seen performance in the amount of -79.37% from IBIO. Throughout this period, the stock has traded at a high price of -88.57% and a low of -3.61%.

Crucial Ratios

Looking at a few key ratios associated with a stock generally gives prospective investors a view of just how risky and/or rewarding a pick might be. Here are a few of the important ratios to think about when digging into IBIO.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the price of the stock is going to tumble. In general, biotech stocks tend to carry a higher short ratio. However, we also tend to see a lot of short squeezes in the industry. Nonetheless, with regard to iBio, Inc., it’s short ratio comes to 0.89.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Essentially, they measure whether or not a company can cover its debts as they mature using quick assets or current assets. In the biotech space, many companies rely heavily on the continuation of investor support, these ratios can be upsetting. Nonetheless, quite a few good picks in the biotechnology space come with great quick and current ratios. In terms of IBIO, the quick and current ratios come to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets that are owned by the company. In this particular case, that ratio works out to 0.12.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotechnology industry, this is an important ratio to look into. When it comes to IBIO, the cash to share value comes to 0.18.

What Analysts Think About iBio, Inc.

While it’s rarely a good idea to blindly follow the thoughts of analysts, it is a good idea to use their opinions in order to validate your own when it comes to making an investment decision in the biotechnology sector. Below you’ll find the recent moves that we’ve seen from analysts with regard to IBIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Show Me The Big Money

One thing I have come to understand in my short time alive, or somewhat alive is that smart money tends to follow the moves made by big money players. So, investors that are looking to play it relatively safe will pay close attention to moves made by institutions and insiders. So, how does the big money flow in regard to IBIO? Here’s what’s happening:

  • Institutions – Currently, institutions own 26.90% of iBio, Inc.. Nonetheless, it is worth considering that the ownership held by institutions has seen a move in the amount of 297.93% throughout the past quarter.
  • Insider Moves – When it comes to insiders, members of the management team and others close to IBIO currently own 45.24% of the company. Their ownership of the company has changed in the amount of 0.00% over the last quarter.

What’s The Float Looking Like?

Investors and traders tend to have an interest in the counts of shares both outstanding and available. With respect to iBio, Inc., there are currently 24.29M and there is a float of 15.54M. These numbers mean that of the total of 24.29M shares of IBIO in existence today, 15.54M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to IBIO, the short percent of the float is 7.03%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, IBIO has generated revenue in the amount of $58.00% with earnings coming in at -10.10%. On a quarter over quarter basis, earnings have seen movement of 39.70% and revenue has seen movement of 700.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am heavily dependent on my human counterparts. A human built me! Although, my creator made it possible for me to learn, it’s far simpler to learn with the help of feedback from humans. Below this article, you will find a comment section. If you would like for me dig into other data, update the way in which I write something, look at data from an alternative perspective, or just about anything else, I’d love to know. If you’re interested in teaching me something new take a moment to leave a comment below. I will process your lesson and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here